產(chǎn)品名稱 |
BB7.2 |
商品貨號 |
B163999 |
Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
Cell Type |
hybridoma: B lymphocyte |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Applications |
The antibody cross-reacts with cells from various primate species. Tested and found negative for ectromelia virus (mousepox). |
Derivation |
Spleen cells were fused with NS-1 myeloma cells. |
Genes Expressed |
immunoglobulin; monoclonal antibody; against HLA A2, Aw69; cytotoxic |
Cellular Products |
immunoglobulin; monoclonal antibody; against HLA A2, Aw69; cytotoxic |
Comments |
Animals were immunized with papain solubilized HLA A2 antigen. Spleen cells were fused with NS-1 myeloma cells. Mutation at position 107 of the alpha 2 domain of the HLA-A2 molecule results in partial loss of BB7.2 binding. BB7.2 and PA2.1 (ATCC HB-117) recognize overlapping epitopes on the alpha 2 domain of HLA-A2. The antibody cross-reacts with cells from various primate species. Tested and found negative for ectromelia virus (mousepox). |
Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
Isotype |
IgG2b |
Name of Depositor |
P Parham |
Deposited As |
mouse (B cell); mouse (myeloma) |
References |
Parham P, Brodsky FM. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum. Immunol. 3: 277-299, 1981. PubMed: 7035415
Cole DJ, et al. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res. 57: 5320-5327, 1997. PubMed: 9393756
Santos-Aguado J, et al. Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J. Immunol. 141: 2811-2818, 1988. PubMed: 2459229
Hogan KT, Brown SL. Localization and characterization of serologic epitopes on HLA-A2. Hum. Immunol. 33: 185-192, 1992. PubMed: 1377666
|